<DOC>
	<DOCNO>NCT00718341</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy multiple dos AFQ056 patient Fragile X Syndrome . The dose range 50 150 mg b.i.d . The primary read-out efficacy reduction Aberrant-Behavior Checklist score .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability AFQ056 Fragile X Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male , nonsmoking patient 18 35 year age ( inclusive ) . Patients fmr1 full mutation ( &gt; 200 CGG repeat ) Patients Clinical Global Impression Severity Score ( CGIS ) &gt; 4 ( moderately ill ) Patients score &gt; 20 ABCC scale ( screen ) Patients mental age â‰¥ 48 month measure StanfordBinet test Patients DSMIV diagnosis schizophrenia , history and/or presence psychosis , confusional state and/or repeat hallucination . Patients history seizure past 5 year without therapeutic treatment control disorder . Patients stable anticonvulsant therapy experience seizure 2 year prior randomization Patients ECG abnormality , autonomic dysfunction , bronchospastic disease , drug atopic allergy Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug Patients use ( use within four week randomization ) concomitant medication potent inhibitor CYP3A4 ( e.g. , ketoconazole , ritonavir , etc . ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Fragile X Syndrome , adult , efficacy</keyword>
</DOC>